Pfizer, starboard value
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
16hon MSN
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Financial writer highlights activist investor Starboard Value's push for Kenvue (KVUE) to divest its challenged skin, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback